Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression
Greene T. et al, (2025), Clinical Journal of the American Society of Nephrology, 20, 632 - 641
Preface
Sawan M. et al, (2025), Proceedings of 2024 3rd International Conference on Public Health and Data Science, ICPHDS 2024
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models.
Di Angelantonio E. et al, (2025), Eur Heart J
Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease.
Hammami I. et al, (2025), Heart
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2024), N Engl J Med
ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL
Judge P. et al, (2024), Nephrology Dialysis Transplantation
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial.
Petrucci G. et al, (2024), Eur Heart J, 45, 1355 - 1367
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study
MIHAYLOVA B. et al, (2024), The Lancet Regional Health - Europe
Thromboxane biosynthesis and risk of future events in diabetes mellitus: A sub-study of the ASCEND trial.
PARISH S. et al, (2023), European Heart Journal
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Mayne K. et al, (2023), Journal of the American Society of Nephrology
Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial
HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial
Judge P. et al, (2023), Lancet Diabetes and Endocrinology
Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model
Wu R. et al, (2023), British Journal of General Practice